United Therapeutics Announces Full Enrollment Of TETON-PPF Study Evaluating Use Of Tyvaso Inhalation Solution For Treatment Of Progressive Pulmonary Fibrosis; Topline Data Expected In H2 Of 2027
Approximately 200,000 patients in the United States have PPF, with limited treatment optionsTopline data expected in the second half of 2027United Therapeutics Corporation (Nasdaq: UTHR) announced full enrollment of its
United Therapeutics finished enrolling all patients for a big study testing whether their medicine Tyvaso can help people with a serious lung disease called PPF. We'll find out if it works in late 2027, which is an important milestone to watch for this company.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.